Please assess the completion status of the following clinical trial:

Trial Title: Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF defined as: with 2 CF-causing mutations, chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities~* Subjects who weigh ≥15 kg without shoes at Screening Visit~* Subjects who are homozygous for the F508del-CFTR mutation~* Subjects with percent predicted forced expiratory volume in 1 second (FEV1) of 70% to 105% (inclusive) (Part A) or ≥40% (Part B) at Screening Visit where the predicted values are adjusted for age, sex, and height using the Wang equation~* Subjects with stable CF disease and who are willing to remain on stable CF medication regimen~* Able to swallow tablets~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1 of the study~* Abnormal liver function as defined in the protocol at Screening Visit~* Abnormal renal function as defined in the protocol at Screening Visit~* History of solid organ or hematological transplantation~* Ongoing participation in an investigational drug study or prior participation in an investigational drug study within 30 days prior of Screening Visit~* History or evidence of lens opacity or cataract at Screening Visit~* Colonization with organisms associated with a more rapid decline in pulmonary status at Screening Visit (Part A only)~* A standard 12-lead ECG demonstrating QTcF \>450 msec at Screening Visit

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Lumacaftor/Ivacaftor (LUM/IVA) (Type: EXPERIMENTAL): Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).